Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208,145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.
Iliopoulos O, Iversen AB, Narayan V, Maughan BL, Beckermann KE, Oudard S, Else T, Maranchie JK, Goldberg CM, Fu W, Perini RF, Liu Y, Linehan WM, Srinivasan R, Jonasch E. Iliopoulos O, et al. Among authors: liu y. Lancet Oncol. 2024 Oct;25(10):1325-1336. doi: 10.1016/S1470-2045(24)00389-9. Epub 2024 Sep 13. Lancet Oncol. 2024. PMID: 39284337 Clinical Trial.
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.
Else T, Jonasch E, Iliopoulos O, Beckermann KE, Narayan V, Maughan BL, Oudard S, Maranchie JK, Iversen AB, Goldberg CM, Fu W, Perini RF, Liu Y, Linehan WM, Srinivasan R. Else T, et al. Among authors: liu y. Clin Cancer Res. 2024 May 1;30(9):1750-1757. doi: 10.1158/1078-0432.CCR-23-2592. Clin Cancer Res. 2024. PMID: 38393723 Free PMC article. Clinical Trial.
Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study.
Wiley HE, Srinivasan R, Maranchie JK, Chhablani J, Iversen ABB, Kruse A, Jonasch E, Gombos DS, Else T, Demirci H, Maughan BL, Hartnett ME, Coleman HR, Fu W, Perini RF, Liu Y, Linehan WM, Chew EY; LITESPARK-004 Investigator Group - Ocular VHL. Wiley HE, et al. Among authors: liu y. Ophthalmology. 2024 Nov;131(11):1324-1332. doi: 10.1016/j.ophtha.2024.05.024. Epub 2024 Jun 6. Ophthalmology. 2024. PMID: 38849055 Clinical Trial.
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.
Jonasch E, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Dror Michaelson M, Appleman LJ, Roy A, Perini RF, Liu Y, Choueiri TK. Jonasch E, et al. Among authors: liu y. Eur J Cancer. 2024 Jan;196:113434. doi: 10.1016/j.ejca.2023.113434. Epub 2023 Nov 15. Eur J Cancer. 2024. PMID: 38008031 Clinical Trial.
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling.
Marathe DD, Jauslin PM, Kleijn HJ, de Miranda Silva C, Chain A, Bateman T, Shaw PM, Abraham AK, Kauh EA, Liu Y, Perini RF, de Alwis DP, Jain L. Marathe DD, et al. Among authors: liu y. CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1499-1510. doi: 10.1002/psp4.13028. Epub 2023 Aug 28. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37596839 Free PMC article.
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, Sumrall A, Baehring J, van den Bent M, Bähr O, Lombardi G, Mulholland P, Tabatabai G, Lassen U, Sepulveda JM, Khasraw M, Vauleon E, Muragaki Y, Di Giacomo AM, Butowski N, Roth P, Qian X, Fu AZ, Liu Y, Potter V, Chalamandaris AG, Tatsuoka K, Lim M, Weller M. Omuro A, et al. Among authors: liu y. Neuro Oncol. 2023 Jan 5;25(1):123-134. doi: 10.1093/neuonc/noac099. Neuro Oncol. 2023. PMID: 35419607 Free PMC article. Clinical Trial.
Standard: Human gastric cancer organoids.
Tan R, Hong F, Wang T, Zhong N, Zhao H, Xu RH, Shen L, Liu Y, Yao X, Xiang D, Gao D, Xiong J, Hui L, Zhao B, Miao Z, Hao J, Li Y, Hu S, Fu B, Hua G, Wang L, Zeng ZL, Chen C, Wu J, Wang C, Wang C, Zhan X, Song C, Sun Z, Yu C, Yang Y, Niu G, Wang Y, Zhao T, Chen YG. Tan R, et al. Among authors: liu y. Cell Regen. 2024 Dec 27;13(1):33. doi: 10.1186/s13619-024-00217-7. Cell Regen. 2024. PMID: 39729207
208,145 results
You have reached the last available page of results. Please see the User Guide for more information.